← back to search

Wojciech Szeliga

Michigan Center for Translational Pathology · US
Area of research
Immunology · Oncology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immune cells in cancer, Immune Cell Function and Interaction, and Ferroptosis and cancer prognosis.
h-index
28
citations
14,132
works
114
NIH funding
primary concept
Medicine
email

Recent publications

Metabolism drives macrophage heterogeneity in the tumor microenvironment
Cell Reports 2022cited by 159position: middledoi
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
Nature Medicine 2021cited by 956position: middledoi
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
Cancer Cell 2021cited by 154position: middledoi
Cancer SLC43A2 alters T cell methionine metabolism and histone methylation
Nature 2020cited by 609position: middledoi
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
Nature 2019cited by 2,801position: middledoi
Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11
Cancer Discovery 2019cited by 1,047position: middledoi
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
Journal of Clinical Investigation 2018cited by 598position: middledoi
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Nature 2015cited by 1,173position: middledoi
Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction
Nature Immunology 2015cited by 403position: middledoi
IL-22+CD4+ T Cells Promote Colorectal Cancer Stemness via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L
Immunity 2014cited by 402position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Weiping Zou · University of Michigan6 papers (2014–2022)Ilona Kryczek · Michigan Cancer Research Consortium6 papers (2014–2022)Linda Vatan · Parker Institute for Cancer Immunotherapy6 papers (2014–2022)Shuang Wei · Hubei University of Medicine5 papers (2015–2022)Lili Zhao · Children’s Hospital of Fudan University Xiamen Branch4 papers (2014–2018)Arul M. Chinnaiyan · BioSurfaces (United States)4 papers (2015–2022)Ende Zhao · Union Hospital3 papers (2014–2015)Michael D. Green · University of Pittsburgh3 papers (2018–2022)Yali Dou · University of Southern California2 papers (2014–2015)Long Jiang · Yanbian University Hospital2 papers (2019–2022)Rebecca Liu · University of British Columbia2 papers (2015–2015)Dongjun Peng · Michigan Medicine2 papers (2014–2015) · 2 papers (2015–2015)Jiali Yu · Cornell University2 papers (2019–2022)Nisha Nagarsheth · National Cancer Institute2 papers (2014–2015)Theodore S. Lawrence · U-M Rogel Cancer Center2 papers (2018–2019)Marcin Cieślik · Icahn School of Medicine at Mount Sinai2 papers (2019–2022)Shanshan Wan · University of Michigan–Ann Arbor1 papers (2015–2015)Zhuwen Wang · University of Michigan–Ann Arbor1 papers (2022–2022) · 1 papers (2015–2015)